GL1X · GenesisL1 explorer

MolNFT v1 · #70956 · protein

Crystal structure of ferredoxin-NADP+ oxidoreductase from bacillus subtilis (form II)

3LZX · Ferredoxin--NADP reductase 2: “Crystal structure of ferredoxin-NADP+ oxidoreductase from bacillus subtilis (form II)”. X-ray diffraction, 3 ligands (FAD, NAP, NA), 5 pockets (best druggability 0.75). MolNFT v1 #70956 on GenesisL1…

PDB
3LZX
Type
protein
Length
658 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Ferredoxin--NADP reductase 2
EC
1.18.1.2
UniProt
O05268
Ligands
FAD, NAP, NA
Pockets
5 · best druggability 0.75

Structure

x-ray diffraction · 1 distinct chain · 26% helix, 31% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BFerredoxin--NADP reductase 2 (EC 1.18.1.2)protein32926% helix, 31% strandO05268

Ligands and binding sites

  • FAD · Flavin-adenine dinucleotide · ligand · 2 copies · chains A, B
  • NAP · Nadp nicotinamide-adenine-dinucleotide phosphate · ligand · 2 copies · chains A, B
  • NA · Sodium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12530.750.8853FAD
23750.730.8465FAD
3670.650.9318empty
44560.620.7655NAP
51980.460.7437NAP

Interfaces

1 interface between chains.

  • A–B · 1786 Ų buried · 31 hydrogen bonds · protein-protein

Compared structures

  • 3LZX · Crystal structure of ferredoxin-NADP+ oxidoreductase from Bacillus subtilis (FORM II) · the same entry in another collection · chain A against A, TM-score 1.00
  • O05268 · AlphaFold monomer V2.0 prediction for ferredoxin--NADP reductase 2 (O05268) · a predicted model of the same protein · chain B against A, TM-score 0.85

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.